In multiple myeloma, malignant plasma cells are localized in marrow and rarely circulate in peripheral blood. To investigate the role of adhesion proteins in this process, we determined the expression and function of adhesion molecules on cell lines derived from patients with myeloma. The U266, ARH-77, IM-9, and HS-Sultan cell lines strongly expressed p1 and a4 integrins (89% t o 98% positive), confirming that VLA-4 is the principal integrin on these cell lines. The U266 and IM-9 cell lines also expressed cs, integrin on 15% t o 20% cells. In contrast, all lines lacked cell surface d, A, and a6 integrin expression (<5% positive). These cell lines adhered t o fibronectin (20% t o 40% specific binding), without significant binding t o either collagen or laminin. Adhesion of these cell lines t o fibronectin was partially blocked with either anti-pl integrin monoclonal antibody (MoAb) (75% inhibition), a n t i -d integrin MoAb (75% inhibition), or RGD peptide (50% inhibition), but was unaffected by anti-wp3 or N MOST CASES of multiple myeloma, the malignant I plasma cells or plasmablasts are localized in the bone marrow (BM) and rarely circulate in the peripheral blood. Antiidiotypic antibody, as well as phenotypic studies, confirm that malignant pre-B and B cells can be found in peripheral blood in the setting of myel~mal-~; however, circulating plasma cells occur only rarely, with the late development of plasma cell leukemia. Preliminary studies suggest that myeloma cells cannot bind to rat highendothelial venules (HEV), consistent with their lack of migration into peripheral blood.4 In contrast, plasma cell leukemia cells do adhere to rat HEV, facilitating their exit into the circulation. Nonetheless, the mechanisms by which myeloma cells localize to the BM, via binding either to extracellular matrix proteins (ECMs) or to myeloma marrow stroma, remain undefined.
In multiple myeloma, malignant plasma cells are localized in marrow and rarely circulate in peripheral blood. To investigate the role of adhesion proteins in this process, we determined the expression and function of adhesion molecules on cell lines derived from patients with myeloma. The U266, ARH-77, IM-9, and HS-Sultan cell lines strongly expressed p1 and a4 integrins (89% t o 98% positive), confirming that VLA-4 is the principal integrin on these cell lines. The U266 and IM-9 cell lines also expressed cs, integrin on 15% t o 20% cells. In contrast, all lines lacked cell surface d, A, and a6 integrin expression (<5% positive). These cell lines adhered t o fibronectin (20% t o 40% specific binding), without significant binding t o either collagen or laminin. Adhesion of these cell lines t o fibronectin was partially blocked with either anti-pl integrin monoclonal antibody (MoAb) (75% inhibition), a n t i -d integrin MoAb (75% inhibition), or RGD peptide (50% inhibition), but was unaffected by anti-wp3 or N MOST CASES of multiple myeloma, the malignant I plasma cells or plasmablasts are localized in the bone marrow (BM) and rarely circulate in the peripheral blood. Antiidiotypic antibody, as well as phenotypic studies, confirm that malignant pre-B and B cells can be found in peripheral blood in the setting of myel~mal-~; however, circulating plasma cells occur only rarely, with the late development of plasma cell leukemia. Preliminary studies suggest that myeloma cells cannot bind to rat highendothelial venules (HEV), consistent with their lack of migration into peripheral blood. 4 In contrast, plasma cell leukemia cells do adhere to rat HEV, facilitating their exit into the circulation. Nonetheless, the mechanisms by which myeloma cells localize to the BM, via binding either to extracellular matrix proteins (ECMs) or to myeloma marrow stroma, remain undefined.
Several adhesion molecules have been defined that mediate cellular interactions and cellular migration. The known cellular adhesion molecules can be divided into at least three families: the Ig gene superfamily, the selectins, and the integrin family.s The integrin family, which is important in dynamic regulation of adhesion and migration, consists of a series of related ap heterodimers involved in a variety of cell to matrix (pl and p3) and cell to cell (p2) adhesion functions. Three subfamilies of integrins can be distinguished by their p subunits: these are known as the anti-allbp3 MoAbs. Moreover, the combination of anti-61 plus RGD peptide or a n t i -d plus RGD peptide inhibited binding t o fibronectin by 80% and 95%, respectively. Finally, pretreatment and coculture of the IM-9 cell line with interleukin-6 (IL-6) resulted in a 52% decrease in specific binding t o fibronectin (30% k 6% t o 15% f 6%; P = .001), associated with a decrease in the number of cells expressing VLA-4 and a decrease in intensity of VLA-4 expression. These data suggest that myeloma cells adhere t o fibronectin through VLA-4 as well as through RGD-dependent mechanisms, and that this binding can be downregulated by IL-6. Future studies of binding of both myeloma cell lines and freshly isolated tumor cells t o extracellular matrix proteins and t o marrow stroma may enhance our understanding of localization and trafficking of cells within the bone marrow microenvironment.
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pl(CD29), P2(CD18) and P3(CD61) integrins? Members of the p l integrin subfamily (also called VLA proteins) contain the p l subunit in association with one of at least six different a subunits and include receptors that bind to the ECMs fibronectin, laminin, and collagen. VLAl(alp1) and VLA2(a2pl) are the receptors to collagen and laminin; VLA3(a3pl) mediates binding to fibronectin and laminin, VLA4(a4pl) and VLAS(aSp1) bind to fibronectin; and VLA6(a6pl) adheres to laminin6 (Table 1) .
Preliminary studies of marrow myeloma cells suggest that they lack a2p1, a3p1, or a6pl and have only variable expression of a4pl integrin~.~ The lack of a2pl and a6pl expression is consistent with their inability to invade endothelial basement membranes, which are composed of collagen type IV and laminin. LFA-1 is a p2 integrin that binds to its receptors, ie, intercellular adhesion molecule (1CAM)-1 and ICAM-2.R39 LFA-1/ICAM interactions are required for the induction of a broad spectrum of leukocyte functions such as cytotoxicity,1° proliferation,ll and differentiation,12 as well as lymphocyte binding to activated endothelial cells in migration and h~m i n g . '~. '~ Although normal plasma cells lack LFA-1, expression of LFA-1 on malignant plasma cells is correlated with proliferation, suggesting that cellular contact is critical for proliferation of malignant plasma cells in myeloma.l5 Finally, the strong expression of the lymphocyte homing receptor CD44 on the majority of myelomas, plasma cell leukemias, and myeloma cell lines is of particular interest because CD44 has been linked to site-specific extravasation of lymphocytes into tissues, sitedirected homing capabilities in B and T lymphocytes, and binding to ECMs. 16 Studies of these and other adhesion molecules on malignant plasma cells may help to gain insight into processes of growth, spread, and clinical behavior of multiple myeloma.
In the present study, we attempted to identify the adhesion molecules on the surface of five myeloma-derived cell lines and to examine their role in adhesion to ECMs. On the U266, ARH-77, IM-9, and HS-Sultan human myeloma-derived cell lines, VLA-4 is the principal integrin expressed; these cell lines adhered to fibronectin, with little or no binding to either collagen or laminin, consistent with 
MATERIALS AND METHODS
The U266," RPMI-8226,18 HS Sultan,19 IM-9," and ARH-77z1 human myeloma-derived cell lines and the SW626 human ovarian cancer cell linez2 were obtained from the American Type Culture Collection (Rockville, MD). Cells were cultured in RPMI 1640 containing 10% to 15% fetal bovine serum (FBS), 100 U/mL penicillin, and 100 pg/mL streptomycin (GIBCO, Grand Island, NY).
The cell surface expression of adhesion molecules was determined using specific MoAbs (Table 2) Myeloma cell lines were radiolabeled with W r (1 mCi/mL) in saline for 1 hour. Cells were suspended at 5 x lo5 cells/mL in RPMI-1% BSA, and 100 p L was added to each well. After incubation at 37°C for 30 minutes, the nonadherent cells were removed by aspiration and inverted centrifugation (1,500 rpm for 10 minutes) or washing with 1% BSA in RPMI media. Remaining bound cells were lysed with 0.1% NP-40 in distilled water, and the radioactivity in cell lysates analyzed using a gamma counter (LKB, WallacOy, Finland).
To characterize the binding of myeloma cell lines to ECMs, antibodies known to specifically abrogate binding were used. Each cell line was preincubated and cultured with 4B4 MoAb (1:50), HP2/1 MoAb (20 pg/mL), LM 609 (1:1,000), P2 (l:lO), GRGDSP peptide (1 mg/mL), or GRGESP peptide (1 mg/mL) in an attempt to block binding to fibronectin. GRGDSP and GRGESP peptides were obtained from Telios Pharmaceuticals, Inc (San Diego, CA).
Myeloma cell lines were next cultured with mitogens or growth factors to characterize their effects on adherence of cell lines to ECMs. The effect of IL-6 on adhesion was determined because IL-6 is known to be a growth factor for myeloma cell as well as myeloma ~e l l s .~~,~~-~ Recombinant IL-6 was kindly provided by Genetics Institute (Cambridge, MA). Each cell line was preincubated and cultured with IL-6 (20 U/mL) in the ECM adherence assay. Cell lines were also cultured with 15 ng/mL phorbol ester Assays of adhesion to ECMs. Monoclonal antibodies were used in an indirect immunofluorescence assay to identify cell surface expression of adhesion molecules. They were also used in blocking experiments to determine specificity of cell line binding to ECM proteins.
For personal use only. on October 23, 2017. by guest www.bloodjournal.org From myristate acetate (PMA), obtained from Sigma Chemicals, because PMA has been reported to modify cellular adhesion mediated by a5pl and a4pl integrin~.~' Specific binding to ECMs was assayed as described above. In addition, cell lines were examined for the percentage and intensity of pl, a3, a4, and 015 integrin expression before and after culture with IL-6 or PMA.
RESULTS
Expression of adhesion molecules on human myeloma cell lines. Five human myeloma cell lines were examined for their cell surface expression of adhesion molecules, including pl and p2 integrins as well as CD56 and CD44, using indirect immunofluorescence techniques ( Table 3 ). The majority (84% to 98%) of cells of the U266, ARH-77, IM-9, and HS-Sultan lines strongly reacted with MoAbs directed at pl integrin and a4 integrin, confirming the presence of VLA-4 on their cell surface. RPMI-8226, in contrast, expressed lower levels of p l (41%) and a4 (13%) integrins, suggesting that pl integrin may be associated with another a subunit on these cells. Indeed, a 3 integrin is expressed on 10% of RPMI-8226 cells as well as a minority of U266 (22%) and IM-9 (15%) cells. None of the cell lines express 1x2, a5, or a 6 integrins. The majority ( 2 85%) of ARH-77, IM-9, and HS-Sultan cells reacted with MoAbs directed at p2 and a L integrins, whereas only 25% of RPMI-8226 cells and few, if any, U266 cells do so. aM integrin is expressed on 55% HS-Sultan cells, but on fewer than 20% cells of the other lines examined. One third of HS Sultan cells bear ax integrins, but the other cell lines lack this adhesion molecule. Significant expression of vitronectin receptor avp3 (CD51) and aIIbp3 (CD4la), known to be receptors for the ligand fibronectin, was noted only on IM-9 cells (22% avp3 positive) and ARH-77 cells (67% aIIbp3 positive). CD44, an adhesion molecule that mediates hyaluronate or collagen binding, was expressed on the majority (> 95%) of U266, ARH-77, and IM-9 cells and on nearly one half of HS Sultan cells. Finally, HS Sultan was the only cell line to significantly (37% cells) express CD56, the NCAM mole- cule that binds to other NCAM bearing cells, thereby mediating homotypic adhesion.
Characterization of adhesion of myeloma cell lines to extracellular matrix proteins. The myeloma cell lines were assayed for their adhesion to ECMs including fibronectin, laminin, as well as human and bovine collagen. As can be seen in Fig 1, the U266 , ARH-77, HS-Sultan, and IM-9 cell lines adhered to fibronectin (25% to 42% specific binding), whereas RPMI-8226 cells did not bind to this ECM.
Minimal (5% to 10%) binding of U266 and IM-9 cells was noted to bovine collagen and laminin. Otherwise no binding of the cell lines to human collagen, bovine collagen, or laminin was observed. The SW626 human ovarian cancer cell line adhered to human collagen, bovine collagen, and laminin (28% to 49% specific binding), but did not bind to fibronectin and, therefore, served as a control for specific ECM binding.
To confirm that the binding of myeloma cell lines to fibronectin was mediated by pl integrin, attempts were made to block adherence to fibronectin by both preincubation and culture of cell lines with the anti-4B4 (CD29) MoAb, which neutralizes p l integrin related binding. The adhesion of U266, ARH-77, IM-9, and HS-Sultan cells to fibronectin was inhibited approximately 50% by anti-4B4
MoAb, confirming a role for the pl integrins in this process (Fig 2) . To further define the molecules involved in fibronectin binding, U266 cells were preincubated and cultured with anti pl integrin (4B4) MoAb, apti-a4 integrin (HP 2/1) MoAb, and/or RGD peptide at titers known to maximally block adhesion. As can be seen in Fig 3, specific binding of U266 cells to fibronectin in the presence of anti-pl (4B4) MoAb, anti-a4 (HP 2/1) MoAb, and excess RGD peptide was 75%, 75%, and 50% blocked, respectively. Excess RGE peptide, which differs from RGD peptide by a single amino acid and does not serve as a binding site on fibronectin, was used as a control and did not abrogate binding of U266 cells to fibronectin. Anti-avp3 (LM609) MoAb and anti-aIIbp3 (P2) MoAb, which bind to RGD peptide on fibronectin, also had no effect on binding of U266 to fibronectin. The combination of 4B4 MoAb plus RGD peptide inhibited binding to fibronectin by 80%, a significant increase in blocking (P = .015) relative to that noted with RGD peptide alone (Fig 3) . Inhibition of binding was similarly increased to 95% by culture with HP 2/1 MoAb and RGD peptide, also a significant increase in blocking (P = . O S ) relative to that noted with RGD peptide alone. Conversely, culture of cells with either HP 2/1 MoAb plus RGD peptide or with 4B4 MoAb plus RGD peptide did not significantly augment inhibition of fibronectin binding relative to that noted in the presence of 4B4 MoAb or HP 2/1 MoAb alone. Finally, preincubation and culture of U266 cells with either anti-avp3 (LM 609) or aIIbp3 (P2) MoAbs did not abrogate binding to fibronectin.
The effect of preincubation and culture of cell lines with IL-6, known to trigger DNA synthesis by these cells,4l or with PMA, shown to alter adhesion mediated by d p l and a4pl integrin~,~' on adhesion to fibronectin was next examined. As can be seen in Fig 4, 
P = .MI). Although pretreatment and culture of ARH-77
cells with IL-6 also decreased specific binding to fibronectin by 41% (32% +-5% to 19% 2 15%), this was not significantly different (P = .228). Culture of cell lines with PMA resulted in increased adhesion to fibronectin, with increments of 8% for IM-9 cells (n = 6, P = .076), of 15% for HS-Sultan cells (n = 3, P = .047), of 19% for U266 cells (n = 3, P = .Ml), and of 34% for ARH-77 cells (n = 3, P = .M2) (Fig 4) .
The effect of similar treatment with IL-6 or PMA on PI, a3, a4, and a5 integrin cell surface expression on these cell lines was measured using indirect immunofluorescence flow cytomctry ( Table 4) . Culturc of these cell lines with IL-6 or PMA did not alter ccll surfacc expression of a3 or a5 integrins. Moreover, treatment with IL-6 lead to only a 13% 2 6% (n = 3, P = .292) and 13% 2 2% (n = 3, P = .031) decrease in p1 and a4 integrins, respectively. Although decreases in pl and a4 integrin expression on ARH cells were observed after IL-6 treatment ( Table 4) , these changes were neither reproducible nor significant. There were no effects of IL-6 treatment on cell surface p1 or a4 integrin exmession on U266. RPMI-8226. and HS-Sultan cells. can hc seen in Fig 5A, of p1 and a4 integrin on IM-9 was dccrcascd by treatmcnt with IL-6. from 5.1 to 2.9 for p1 intcgrin and from 4.9 to 2.9 for a4 intcgrin. Similarly, the mcan peak fluoresccncc intensity of PI and a4 intcgrin exprcssion on ARH-77 cells decreased aftcr stimulation with IL-6 from 4.0 to 3.8 for PI intcgrin and 5.2 to 4.2 for a4 intcgrin (Fig SB) . In contrast, IL-6 trcatmcnt did not alter thc intcnsity of p1 or a4 intcgrin exprcssion on U266 and HS Sultan cells. Culture of ccll lines with PMA did not altcr thc pcrccntagc of cells bearing pl or a4 intcgrins on any mycloma ccll lincs (Tablc 4). Howcvcr, a slight dccreasc in intcnsity of both Pl and a4 intcgrin exprcssion was observed on IM-9 cells aftcr PMA trcatmcnt (Fig SA) .
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DISCUSSION
Adhesion molecules play an important role in migration and homing of mononuclcar cells to facilitate cell to ccll intcractions in the normal immune
In hcmatologic malignancics, adhcsion molecules may also bc crucial in determining thc propcrtics rcquircd for rclcasc of leukemic cclls from thc BM. Indccd thc scqucncc of adhcsion and dctachmcnt is fundamcntal to ccll locomotion and csscntial to malignant invasion.4x In multiplc mycloma, the malignant plasma cells arc localized in thc BM and rarcly circulate in thc pcriphcral blood. Howevcr, little is known of thc mechanisms by which malignant plasma cells adhere to thc BM stroma and how these usually scssile cells uncxpectcdly appear in thc blood. Although normal plasma cclls adhcrc tightly to thc marrow stroma and do not tcnd to migratc, malignant plasma cclls can bc phenotypically divcrgcnt, ic, subscts arc ablc to dctach from thc bonc marrow stroma and migratc to cxtramcdullary sitcs in plasma ccll leukemia? Thus, it is important to charactcrizc thc adhesive propcrties of malignant cells that arc localizcd in BM and to contrast thcm with malignant cclls that have a propensity to invadc basement mcmbrancs and thereby exit from marrow.
Normal pcriphcral blood B cells bcar VLA-4; howcvcr, thc lcvcl of a4 subunit is almost twice the lcvcl of PI dctcctcd, suggcsting that not all of the a4 subunit is associated with PI." Thc cxprcssion of p1 intcgrins on normal plasma cclls is not yct dcfincd. Our studies showed that four human mycloma-dcrivcd ccll lincs also cxprcsscd VLA-4 protcin; howcvcr, in contrast to normal B cclls, the lcvcls of a4 and pl intcgrins on thcsc cclls is cquivalcnt. Thcsc cclls cxprcssing VLA-4 protcin adhcrcd to fibroncctin, and this adhcrcncc could bc partially blockcd with cithcr anti-pl intcgrin or anti-a4 intcgrin MoAbs. Morcovcr, thc binding of thcsc cclls to fibroncctin was also partially blockcd with RGD pcptidc, suggcsting that their binding to fibroncctin is mcdiatcd not only by VLA-4 protcin but also by othcr receptors with fibroncctin binding propcrtics, such as vitroncctin rcccptor (aV intcgrin) or gp IIbIIIa. Phcnotypic and functional studics confirm that avp3 and aI1bp.t are not involved in binding of myeloma ccll lincs to fibroncctin, but othcr vitroncctin receptors, ic, avpl or avpS, remain as possible mediators of fibroncctin binding. Importantly, specific binding to fibronectin could bc nearly complctcly blockcd by the addition of anti-pl or anti-a4 intcgrin MoAb to cxccss RGD pcptidc. Thcsc data suggest that thc ability of mycloma cclls to bind to fibroncctin may contributc to their localization in the bone marrow and, convcrscly, that the loss of fibroncctin receptors may correlate with a propensity to cmigratc from thc bonc marrow microcnvironmcnt. Finally, thcsc cclls do not For personal use only. on October 23, 2017 . by guest www.bloodjournal.org From 
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adhere to collagen and laminin. Because the basal lamina is composed mainly of type IV collagen and lamini11,4~ the lack of receptors for these ECM components also prohibits their transit to extravascular spaces. The high serum levels of IL-6 noted in patients with active coupled with the recent observation that systemic administration of anti-IL-6 may inhibit growth of myeloma cells in vivo,44 strongly supports a role for IL-6 in the pathophysiology of myeloma. Previous studies also suggest a role for IL-6 in growth of human multiple myeloma-derived cell lines."41 In the present study, we showed that IL-6 treatment of the IM-9 myeloma cell lines decreased binding to fibronectin, with a concomitant decrease in VLA-4 cell surface expression. Although the influence of ECM proteins and integrins on the behavior and development of normal plasma cells has not yet been studied, it is known that normal pre-B cells appear to use two different integrin-like fibronectin receptors during migration and maturation in the BM, before losing this capacity upon release into Similarly, maturation of reticulocytes within the BM is associated with loss of adhesion to fibronectin as well as a loss of detectable VLA-Mike complex>l In these examples, it is clear that matrix-to-integrin interactions play a significant role in the development of blood cells. We hypothesize that some malignant plasma cells remain in the BM because of binding to fibronectin. Moreover, changes in adhesion of myeloma cells which are induced by IL-6 in vitro may reflect the in vivo effects of IL-6 on malignant plasma cells, ie, their ability to exit from the BM and circulate in plasma cell leukemia. In our studies, IL-6 induced only small changes in p l and a4 integrin expression. Decreased adhesion to For personal use only. on October 23, 2017. by guest www.bloodjournal.org From fibronectin induced by IL-6 may, therefore, be related to a decrease in affinity of fibronectin receptors.
In the present study, we examined the effect of PMA on expression and function of p l integrins on myeloma cell lines. Treatment with PMA enhanced binding to fibronectin on all myeloma cell lines, but did not upregulate either pl or 014 integrin expression. Therefore, the effect of PMA on cell surface expression was dissociated from its effects on receptor function, and PMA appears to induce an increased affinity for binding to fibronectin. The mechanism whereby PMA enhances integrin-mediated enhancement of cellular adhesion has not been defined. Changes in the functional state of integrins can be induced by PMA, ie, phorbol esters dramatically upregulate binding mediated by 01Lf32 as well as aMP2 integrin.5,s2 Activation with PMA may also result in conformational changes of integrin within the cytoskeleton, thereby altering the distribution of receptorss3: for example, treatment with PMA led to localization of talin with pl integrin in antibody-induced caps on the surface of lymphocytes, consistent with a metabolically regulated change in membrane-cyto~keleton.~~ It has been reported that VLA-4 on B cells mediates binding to germinal center cells only when B cells are activated, ie, with PMA.55 The effects of PMA treatment on adherence of malignant cells are not as well studied. Wilkins et aIs6 reported that the enhanced adherence of human T-cell leukemia cells to ECMs, induced by PMA, did not involve upregulation of receptor expression, but rather was derived from the increased affinity of binding for structures that were expressed on the cell surface. In other studies of pl integrins, PMA has induced a loss of VLA-5 glycosylation, a loss of VLA-5 function, or an increase in VLA-5 expression on leukemic cell lines>7 PMA has also been shown to induce differentiation as well as enhanced adhesion to fibronectin, associated with modulation of VLA-4 and VLAJ fibronectin re~eptors.4~ Finally, recent studies suggest that follicular non-Hodgkin's lymphomas adhere to normal germinal centers via VLA-4 on the tumor cell surface.58 Our studies suggest that VLA-4 may also mediate binding of myeloma cell lines to fibronectin. Moreover, they further suggest that VLA-4 can be upregulated functionally by PMA in vitro, suggesting that they may also be capable of similar functional upregulation in vivo.
The present studies used myeloma-derived cell lines, which may not reflect either the cell surface phenotype or biology of myeloma in vivo. 16 Therefore, in future studies it will be necessary to characterize the function of adhesion molecules on freshly isolated tumor cells from patients with multiple myeloma. Such studies will define mechanisms of adherence not only to ECMs but also to myeloma stromal cells and, thereby, will enhance our understanding of the localization and trafficking of cells within the BM microenvironment. For personal use only. on October 23, 2017 . by guest www.bloodjournal.org From
